France Insulin Drugs And Delivery Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The France Insulin Drugs and Delivery Devices Market is segmented into Drugs (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, and Biosimilar Insulins) and Devices (Insulin Pens, Insulin Pumps, Insulin Syringes, and Jet Injectors). The report offers the value (in USD million) and volume (in million mL) for insulin drugs and (in unit million) for the devices for the above segments.

France Insulin Drugs And Delivery Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

France Insulin Drugs And Delivery Devices Industry Overview

The France Insulin Drugs and Delivery Devices Market is consolidated, with few significant and generic players. Mergers and acquisitions between the players recently have helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim have an alliance in developing and commercializing Basaglar (Insulin Glargine). Additionally, the players in the recent past helped the companies strengthen their market presence; for example, Novo Nordisk collaborated with Ypsomed to provide better insulin therapy solutions.

France Insulin Drugs And Delivery Devices Market Leaders

  1. Novo Nordisk

  2. Eli Lilly

  3. Sanofi

  4. Ypsomed

  5. Medtronic

  6. *Disclaimer: Major Players sorted in no particular order
France Insulin Drugs and Delivery Devices Market Concentration

France Insulin Drugs And Delivery Devices Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?